Contract Research Organization Services Market

Contract Research Organization Services Market / CRO Services Market by Type (Early Phase, Clinical, Lab, Consulting, Data Management), Therapeutic Area (Cancer, Infectious Disease, Neurology, Dermatology, Immunology, Hematology, Vaccines, CGT) - Global Forecast to 2029

Report Code: PH 4672 Jan, 2024, by marketsandmarkets.com

The global contract research organization services market in terms of revenue was estimated to be worth $82.0 billion in 2024 and is poised to reach $129.8 billion by 2029, growing at a CAGR of 9.6% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Growth in the CRO services market is mainly due to the growing number of drug products in development pipeline. Additionally, drug discovery and development costs are high for in-house development of therapeutics and medical devices. This is driving outsourcing of development services to CROs. Also, growing technological advancements are supporting market growth. Moreover, precision/ personalized medicine are areas of growing focus which are an opportunity area for the CROs.

Contract Research Organization Services Market Size, Dynamics & Ecosystem

Contract Research Organization Services Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Contract Research Organization (CRO) Services Market Dynamics

DRIVER: Increasing number of drugs in pipeline

The drug development initiatives have been growing for the decade. The number of drug product entering the development pipeline has been consistently growing. For instance, the size of R&D pipeline has grown from 10,479 products in 2013 to 21,292 in 2023, which is greater than double of the count a decade ago. Thus, the share of outsourcing of drug development processes has also been growing for the past few years. The sponsors such as pharmaceutical and biotechnology companies and academic institutes outsource drug development activities with an aim to leverage on the capabilities of CROs including required infrastructure, therapeutic expertise, regulatory expertise among others. Therefore, increasing R&D pipeline is driving the growth of the CRO services market.

OPPORTUNITY: Growing focus on precision/ personalized medicine

The research and development initiatives in the area of precision / personalized medicine have been growing since 2015. There has been a consistent growth in the number of products approved as personalized medicines by the US FDA. For instance, the US FDA has approved more than 50 drugs as personalized medicines between 2020 and 2022 which was merely 12 drugs in 2019. Additionally, CROs have also started offering special services for precision/ personalized medicines as well. This is attracting pharmaceutical and Biotech compenie to outsource these trials from CROs as well. Some instances of companies offering associated services include Labcorp, IQVIA, among others.

CHALLENGE: Patient recruitment and retention

Patient recruitment is the enrolment of patients into clinical trials at different stages. It is a significant part of the clinical trials outcome. Effective patient recruitment along with retention throughout the trial is crucial for the success of any clinical trial. Patient recruitment has always been a challenge in the overall drug development process. This is mainly due to several reasons such as- lack of awareness, complexities in the inclusion/ exclusion criteria, and some trials with longer durations pose a challenge of retention. Additionally, lack of understanding of the perspective of patients is also a factor responsible for challenges faced in patient recruitment. However, decentralized clinical trials (DCT) are expected to lower the effect of this challenge. Decentralized trials allow efficient patient recruitment as they allow time and place liberty to the participants of the clinical trials. Thus, increasing use of DCT might reduce the effects of this challenge in the coming years.

Contract Research Organization (CRO) Services Market Ecosystem

Prominent companies in the contract research organization services market includes companies operating in the market for several years and posess diversified service portfolio, state-of-the-art technologies, and strong global sales and marketing networks. Prominent companies in the CRO Services market include are IQVIAInc. (US), Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), ICON Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US) among others.

Contract Research Organization Services Market Segmentation & Geographical Spread

Contract Research Organization Services Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

The clinical research services accounted for the largest share of the type segment in overall Contract Research Organization Services Industry in 2023.

On the basis of type, the CRO Services market is segmented into Clinical Research Services, Early Phase Development Services, Laboratory Services, Consulting Services and Data Management Services. In 2023, the clinical research services segment accounted for the largest share of the market owing to a major factor including growing number of clinical trials from phase 1 to 4 and an increase in the outsourcing of clinical research and development activities among others.

The oncology subsegment of the therapeutic area segment dominated the overall Contract Research Organization Services Industry in 2023.

On the basis of therapeutic areas, the CRO Services market is segmented into Oncology, Infectious Diseases, CVS Disorders, Neurology, Vaccines, Metabolic Disorders/Endocrinology, Immunological Disorders, Psychiatry, Respiratory Disorders, Dermatology, Ophthalmology, Gastrointestinal diseases, Genitourinary and Women’s health, Hematology, and other therapeutic areas. Oncology accounted for the largest share of the market owing to factors such as consistently increasing number of clinical trials againt oncology indications, growing research and development funding being channelized for oncology drug development initiatives, and an increasing prevalence of different types of cancers in the coming years.

North America was the largest market for overall Contract Research Organization Services Industry in 2023 and also during the forecast period.

Geographically, the CRO Services market is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and Africa. The market was dominated by North America in 2023 and this dominance is anticipated to continue throughout the forecast period between 2024 and 2029. The market for CRO Services is expanding in the region as a result of factors like growing size of the pharmaceutical industry in the region, and large funds dedicated to pharma R&D, among others.

The prominent players in the CRO Services market are IQVIA Inc. (US), Laboratory Corporation of America Holdings (US), Thermo Fisher Scientific Inc. (US), ICON Plc (Ireland), WuXi AppTec (China), Syneos Health (US), Charles River Laboratories (US), Fortrea, Inc. (US), Pharmaron (China), Eurofins Scientific (Luxembourg) and Medpace (US) among others.

Scope of the Contract Research Organization Services Industry

Report Metric

Details

Market Revenue in 2024

$82.0 billion

Projected Revenue by 2029

$129.8 billion

Revenue Rate

Poised to Grow at a CAGR of 9.6%

Market Driver

Increasing number of drugs in pipeline

Market Opportunity

Growing focus on precision/ personalized medicine

This report categorizes the Contract Research Organization Services Market to forecast revenue and analyze trends in each of the following submarkets:

By Type

  • Clinical Research Services
    • By Phase
      • Phase III
      • Phase II
      • Phase I
      • Phase IV
    • By Study Design (For Phase III & IV)
      • Interventional
      • Real World Evidence (RWE)
  • Early phase development Services
    • Chemistry, Manufacturing and Controls Services
    • Preclinical Services
      • Pharmacokinetics/ Pharmacodynamics Services
      • Toxicology Testing Services
      • Other Preclinical Services
    • Discovery Studies
  • Laboratory Services
    • Analytical Testing Services
      • Physical Characterization Services
      • Raw Material Testing Services
      • Batch Release Testing Services
      • Stability Testing Services
      • Other Analytical Testing Services
    • Bioanalytical Testing Services
  • Consulting Services
  • Data Management Services

By Therapeutic Area

  • Oncology
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Other Cancer
  • Infectious Diseases
  • CVS Disorders
  • Neurology
  • Vaccines
  • Metabolic Disorders/Endocrinology
  • Immunological Disorders
  • Psychiatry
  • Respiratory Disorders
  • Dermatology
  • Ophthalmology
  • Gastrointestinal Diseases
  • Genitourinary & Women’s Health
  • Hematology
  • Other Therapeutic Areas

By End User

  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Academic Institutes

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • New Zealand
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • Middle East
    • Africa

Recent Developments of Contract Research Organization Services Industry:

  • In October 2023, IQVIA Inc. (US) and argenx (US) entered a strategic collaboration to support treatment for patients suffering from rare autoimmune disorders through innovative and comprehensive technology-enabled pharmacovigilance (PV) safety services and solutions.
  • In October 2023, LabCorp announced the acquisition of the outreach laboratory business and selected operating assets of Baystate Health, comprising laboratory service centres operated by Baystate Health throughout Massachusetts, US.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 66)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS & EXCLUSIONS 
    1.4 MARKET SCOPE 
           1.4.1 MARKETS CONSIDERED
           1.4.2 REGIONS CONSIDERED
           1.4.3 YEARS CONSIDERED
           1.4.4 CURRENCY CONSIDERED
    1.5 RESEARCH LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
           1.7.1 RECESSION IMPACT: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION
 
2 RESEARCH METHODOLOGY (Page No. - 71)
    2.1 RESEARCH DATA 
          FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    FIGURE 2 SECONDARY DATA SOURCES
           2.1.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2023
          FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023
          FIGURE 6 ILLUSTRATIVE EXAMPLE OF IQVIA INC.: REVENUE SHARE ANALYSIS, 2023
          FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
           2.2.1 MARKET SIZE ASSESSMENT AT SEGMENTAL LEVEL
                    FIGURE 8 MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
    2.3 MARKET GROWTH FORECAST 
          FIGURE 9 CAGR PROJECTIONS, 2024–2029
          FIGURE 10 GROWTH ANALYSIS OF DRIVERS, OPPORTUNITIES, AND CHALLENGES IN CRO SERVICES MARKET
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 11 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ANALYSIS 
    2.7 IMPACT OF ECONOMIC RECESSION ON MARKET 
          TABLE 1 GLOBAL INFLATION RATE PROJECTION, 2021–2028 (% GROWTH)
          TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTH EXPENDITURE, 2023–2030 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 83)
    FIGURE 12 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION, BY TYPE, 2024 VS. 2029 (USD MILLION)
    FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2024 VS. 2029 (USD MILLION)
    FIGURE 14 MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
    FIGURE 15 GEOGRAPHICAL SNAPSHOT OF CONTRACT RESEARCH ORGANIZATION SERVICES MARKET
 
4 PREMIUM INSIGHTS (Page No. - 87)
    4.1 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET OVERVIEW 
          FIGURE 16 INCREASING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET
    4.2 NORTH AMERICA: CRO SERVICES MARKET,  BY COUNTRY AND TYPE, 2023 
          FIGURE 17 US AND CLINICAL RESEARCH SERVICES TO DOMINATE NORTH AMERICAN MARKET IN 2023
    4.3 MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION) 
          FIGURE 18 CLINICAL RESEARCH SERVICES TO DOMINATE MARKET DURING STUDY PERIOD
    4.4 MARKET, BY END USER, 2023 
          FIGURE 19 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
    4.5 GEOGRAPHICAL GROWTH OPPORTUNITIES IN CONTRACT RESEARCH ORGANIZATION SERVICES MARKET 
          FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 91)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 DRIVERS, OPPORTUNITIES, AND CHALLENGES: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION
          TABLE 4 IMPACT ANALYSIS: CRO SERVICES MARKET
           5.2.1 DRIVERS
                    5.2.1.1 Rising pharmaceutical R&D expenditure and increasing drug pipeline
                                FIGURE 22 LARGE PHARMACEUTICAL R&D SPENDING (AS A PERCENTAGE OF SALES), 2013–2022
                                FIGURE 23 ACTIVE PHARMACEUTICAL PIPELINE, 2012–2023
                    5.2.1.2 Technological advancements in clinical trials and innovative trial designs
                    5.2.1.3 High cost of in-house drug development
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Favorable growth prospects for biologics and biosimilars market
                                FIGURE 24 BIOSIMILARS APPROVALS AND LAUNCHES, 2015–2022
                    5.2.2.2 Need for novel clinical trial designs for complex cell & gene therapies
                                FIGURE 25 ONGOING CLINICAL TRIALS BY PHASE AND THERAPEUTIC APPROACH  (AS OF APRIL 2023)
                                FIGURE 26 GENE & CELL THERAPY DEVELOPERS, CLINICAL TRIALS, AND INVESTMENT,  BY REGION, 2022
                    5.2.2.3 Emergence of hybrid models with CRO-CDMO partnerships
                    5.2.2.4 Growing focus on personalized/precision medicine
                    5.2.2.5 Development of next-generation biotherapeutic products
           5.2.3 CHALLENGES
                    5.2.3.1 Lack of adequate patient recruitment and retention for clinical trials
                    5.2.3.2 Changing clinical trial complexities
    5.3 MARKET TRENDS 
           5.3.1 INDUSTRY CONSOLIDATION
                    TABLE 5 LIST OF MERGERS AND ACQUISITIONS
           5.3.2 DECENTRALIZED CLINICAL TRIALS
           5.3.3 REAL-WORLD DATA AND REAL-WORLD EVIDENCE
           5.3.4 INCREASING INVOLVEMENT OF ARTIFICIAL INTELLIGENCE
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 27 REVENUE SHIFT AND NEW POCKETS FOR CRO SERVICE PROVIDERS
    5.5 PRICING ANALYSIS 
          TABLE 6 PRICING ILLUSTRATION FOR FIRST IN-HUMAN TRIAL IN HEALTHY VOLUNTEERS IN EUROPE
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 28 VALUE CHAIN ANALYSIS: CLINICAL RESEARCH TO ADD MAXIMUM VALUE
    5.7 ECOSYSTEM ANALYSIS 
          TABLE 7 ROLE IN ECOSYSTEM: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION
    5.8 TECHNOLOGY ANALYSIS 
    5.9 CASE STUDY ANALYSIS 
           5.9.1 PPD TO LEVERAGE ITS PRECLARUS TECHNOLOGY FOR GENERATING CLEANER DATA, FASTER CLINICAL TRIALS, AND LESSER SITE BURDEN
           5.9.2 IQVIA TO OFFER AI-POWERED MODELING FOR BETTER PATIENT IDENTIFICATION
           5.9.3 USE OF LAB DATA INSIGHTS TO IMPROVE POPULATION MANAGEMENT OF CHRONIC KIDNEY DISEASES
           5.9.4 IQVIA TO LEVERAGE ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR IMPROVED SERVICE OFFERINGS
    5.10 KEY CONFERENCES & EVENTS 
           TABLE 8 DETAILED LIST OF KEY CONFERENCES & EVENTS, 2024
    5.11 REGULATORY ANALYSIS 
           5.11.1 REGULATORY ANALYSIS
           5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
                     TABLE 12 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
           5.11.3 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
    5.12 PORTER’S FIVE FORCES ANALYSIS 
           TABLE 13 PORTER’S FIVE FORCES ANALYSIS: MARKET
           5.12.1 THREAT OF NEW ENTRANTS
           5.12.2 THREAT OF SUBSTITUTES
           5.12.3 BARGAINING POWER OF BUYERS
           5.12.4 BARGAINING POWER OF SUPPLIERS
           5.12.5 INTENSITY OF COMPETITIVE RIVALRY
    5.13 KEY STAKEHOLDERS & BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF CRO SERVICES IN PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
           5.13.2 BUYING CRITERIA
                     FIGURE 30 KEY BUYING CRITERIA FOR END USERS
 
6 CRO SERVICES MARKET, BY TYPE (Page No. - 122)
    6.1 INTRODUCTION 
          TABLE 14 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET PREDICTION, BY TYPE, 2022–2029 (USD MILLION)
    6.2 CLINICAL RESEARCH SERVICES 
          TABLE 15 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES, BY LOCATION (AS OF DECEMBER 21, 2023)
          FIGURE 31 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2022 VS. 2023
          TABLE 16 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
          TABLE 17 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
          TABLE 18 CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION,  2022–2029 (USD MILLION)
          TABLE 19 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 20 EUROPE: MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 21 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 22 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 23 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH SERVICES,  BY REGION, 2022–2029 (USD MILLION)
           6.2.1 CLINICAL TRIAL SERVICES MARKET, BY PHASE
           6.2.2 PHASE III CLINICAL RESEARCH SERVICES
                    6.2.2.1 Increased use of clinical resources and advanced technologies to drive segment
                                TABLE 24 EXAMPLES OF DRUGS IN PHASE III OF CLINICAL TRIALS, 2023
                                TABLE 25 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 26 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 27 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 28 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 29 LATIN AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 30 MIDDLE EAST & AFRICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.3 PHASE II CLINICAL RESEARCH SERVICES
                    6.2.3.1 Rising number of pipeline products to propel market
                                TABLE 31 EXAMPLES OF DRUGS IN PHASE II OF CLINICAL TRIALS, 2023
                                TABLE 32 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 33 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 34 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 35 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 36 LATIN AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 37 MIDDLE EAST & AFRICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.4 PHASE I CLINICAL RESEARCH SERVICES
                    6.2.4.1 Growing R&D pipeline of pharmaceutical companies to support segment
                                TABLE 38 EXAMPLES OF DRUGS IN PHASE I OF CLINICAL TRIALS, 2023
                                TABLE 39 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 40 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 41 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 42 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 43 LATIN AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 44 MIDDLE EAST & AFRICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.5 PHASE IV CLINICAL RESEARCH SERVICES
                    6.2.5.1 Increasing number of CROs providing post-marketing surveillance to drive segment
                                TABLE 45 EXAMPLES OF DRUGS IN PHASE IV OF CLINICAL TRIALS, 2023
                                TABLE 46 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 47 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 48 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 49 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 50 LATIN AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 51 MIDDLE EAST & AFRICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.2.6 CLINICAL RESEARCH SERVICES MARKET, BY STUDY DESIGN
                    TABLE 52 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY STUDY DESIGN, 2022–2029 (USD MILLION)
                    TABLE 53 CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY REGION, 2022–2029 (USD MILLION)
                    6.2.6.1 Interventional studies
                               6.2.6.1.1 Better monitoring and data collection with structured protocol to propel segment
                                              TABLE 54 INTERVENTIONAL STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
                    6.2.6.2 Real world evidence studies
                               6.2.6.2.1 Increasing focus on informed healthcare decision-making to boost segment
                                              TABLE 55 REAL WORLD EVIDENCE STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
    6.3 EARLY-PHASE DEVELOPMENT SERVICES 
          TABLE 56 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
          TABLE 57 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 58 CRO SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION,  2022–2029 (USD MILLION)
          TABLE 59 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 60 EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 61 ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 62 LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 63 MIDDLE EAST & AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY REGION, 2022–2029 (USD MILLION)
           6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES
                    6.3.1.1 Growing need to meet regulatory norms in drug development to drive segment
                                TABLE 64 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 65 NORTH AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 66 EUROPE: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 67 ASIA PACIFIC: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 68 LATIN AMERICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 69 MIDDLE EAST & AFRICA: CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
           6.3.2 PRECLINICAL SERVICES
                    TABLE 70 PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 71 PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 72 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 73 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 74 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 75 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 76 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
                    6.3.2.1 Pharmacokinetics/Pharmacodynamics
                               6.3.2.1.1 High significance of drug metabolism studies to drive segment
                                              TABLE 77 PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION,  2022–2029 (USD MILLION)
                                              TABLE 78 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                              TABLE 79 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                              TABLE 80 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                              TABLE 81 LATIN AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET,  BY COUNTRY, 2022–2029 (USD MILLION)
                                              TABLE 82 MIDDLE EAST & AFRICA: PHARMACOKINETICS/PHARMACODYNAMICS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    6.3.2.2 Toxicology testing
                               6.3.2.2.1 Growing need to provide high-quality and safe drugs to drive segment
                                              TABLE 83 TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                              TABLE 84 NORTH AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 85 EUROPE: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 86 ASIA PACIFIC: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 87 LATIN AMERICA: TOXICOLOGY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 88 MIDDLE EAST & AFRICA: TOXICOLOGY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                    6.3.2.3 Other preclinical services
                                TABLE 89 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 90 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 91 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 92 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 93 LATIN AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 94 MIDDLE EAST & AFRICA: OTHER PRECLINICAL SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
           6.3.3 DISCOVERY STUDIES
                    6.3.3.1 Increasing reliance on CRO services for target identification and validation to propel segment
                                TABLE 95 DISCOVERY STUDIES MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 96 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 97 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 98 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 99 LATIN AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 100 MIDDLE EAST & AFRICA: DISCOVERY STUDIES MARKET, BY REGION,  2022–2029 (USD MILLION)
    6.4 LABORATORY SERVICES 
          TABLE 101 EXAMPLES OF LABORATORY SERVICES OFFERED BY MARKET PLAYERS
          TABLE 102 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 103 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY REGION,  2022–2029 (USD MILLION)
          TABLE 104 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 105 EUROPE: CRO SERVICES MARKET FOR LABORATORY SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 106 ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 107 LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 108 MIDDLE EAST & AFRICA: MARKET FOR LABORATORY SERVICES,  BY REGION, 2022–2029 (USD MILLION)
           6.4.1 ANALYTICAL TESTING
                    TABLE 109 ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 110 ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 111 NORTH AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 112 EUROPE: ANALYTICAL TESTING MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 113 ASIA PACIFIC: ANALYTICAL TESTING  MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 114 LATIN AMERICA: ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 115 MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)
                    6.4.1.1 Physical characterization
                               6.4.1.1.1 Growing need to reduce risk of product failures to drive segment
                                              TABLE 116 PHYSICAL CHARACTERIZATION MARKET, BY REGION,  2022–2029 (USD MILLION)
                                              TABLE 117 NORTH AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                              TABLE 118 EUROPE: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 119 ASIA PACIFIC: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 120 LATIN AMERICA: PHYSICAL CHARACTERIZATION MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 121 MIDDLE EAST & AFRICA: PHYSICAL CHARACTERIZATION MARKET, BY REGION, 2022–2029 (USD MILLION)
                    6.4.1.2 Raw material testing
                               6.4.1.2.1 Importance of quality and purity of raw materials to propel segment
                                              TABLE 122 RAW MATERIAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                              TABLE 123 NORTH AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 124 EUROPE: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 125 ASIA PACIFIC: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 126 LATIN AMERICA: RAW MATERIAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 127 MIDDLE EAST & AFRICA: RAW MATERIAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)
                    6.4.1.3 Batch-release testing
                               6.4.1.3.1 Wide range of batch-release testing services offered by CROs to propel growth
                                              TABLE 128 BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                              TABLE 129 NORTH AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 130 EUROPE: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 131 ASIA PACIFIC: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 132 LATIN AMERICA: BATCH-RELEASE TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 133 MIDDLE EAST & AFRICA: BATCH-RELEASE TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                    6.4.1.4 Stability testing
                               6.4.1.4.1 Long-term quality, safety, and efficacy of pharmaceutical products to drive segment
                                              TABLE 134 STABILITY TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                              TABLE 135 NORTH AMERICA: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 136 EUROPE: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 137 ASIA PACIFIC: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 138 LATIN AMERICA: STABILITY TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                              TABLE 139 MIDDLE EAST & AFRICA: STABILITY TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)
                    6.4.1.5 Other analytical testing
                                TABLE 140 OTHER ANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 141 NORTH AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 142 EUROPE: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 143 ASIA PACIFIC: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 144 LATIN AMERICA: OTHER ANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 145 MIDDLE EAST & AFRICA: OTHER ANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)
           6.4.2 BIOANALYTICAL TESTING
                    6.4.2.1 Rising significance of accurate PK/PD studies to drive segment
                                TABLE 146 BIOANALYTICAL TESTING MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 147 NORTH AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 148 EUROPE: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 149 ASIA PACIFIC: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 150 LATIN AMERICA: BIOANALYTICAL TESTING MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 151 MIDDLE EAST & AFRICA: BIOANALYTICAL TESTING MARKET, BY REGION,  2022–2029 (USD MILLION)
    6.5 CONSULTING SERVICES 
           6.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO SUPPORT MARKET
                    TABLE 152 EXAMPLES OF CONSULTING SERVICES OFFERED BY MARKET PLAYERS
                    TABLE 153 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CONSULTING SERVICES, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 154 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 155 EUROPE: CRO SERVICES MARKET FOR CONSULTING SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 156 ASIA PACIFIC: MARKET FOR CONSULTING SERVICES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 157 LATIN AMERICA: MARKET FOR CONSULTING SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 158 MIDDLE EAST & AFRICA: MARKET FOR CONSULTING SERVICES,  BY REGION, 2022–2029 (USD MILLION)
    6.6 DATA MANAGEMENT SERVICES 
           6.6.1 DATA MANAGEMENT SERVICES TO COMMAND HIGHEST GROWTH RATE DURING FORECAST PERIOD
                    TABLE 159 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY MARKET PLAYERS
                    TABLE 160 MARKET FOR DATA MANAGEMENT SERVICES, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 161 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR DATA MANAGEMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 162 EUROPE: MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 163 ASIA PACIFIC: MARKET FOR DATA MANAGEMENT SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 164 LATIN AMERICA: MARKET FOR DATA MANAGEMENT SERVICES,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 165 MIDDLE EAST & AFRICA: MARKET FOR DATA MANAGEMENT SERVICES,  BY REGION, 2022–2029 (USD MILLION)
 
7 CRO SERVICES MARKET, BY THERAPEUTIC AREA (Page No. - 194)
    7.1 INTRODUCTION 
          TABLE 166 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
    7.2 ONCOLOGY 
          TABLE 167 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040
          FIGURE 32 NUMBER OF REGISTERED ONCOLOGY CLINICAL TRIALS,  2012–2023 (THOUSAND)
          TABLE 168 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY, 2023
          TABLE 169 MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 170 MARKET FOR ONCOLOGY, BY REGION, 2022–2029 (USD MILLION)
          TABLE 171 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 172 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 173 ASIA PACIFIC: MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 174 LATIN AMERICA: MARKET FOR ONCOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
          TABLE 175 MIDDLE EAST & AFRICA: MARKET FOR ONCOLOGY, BY REGION,  2022–2029 (USD MILLION)
           7.2.1 BREAST CANCER
                    7.2.1.1 Strong R&D pipeline for breast cancer drugs to drive segment
                                TABLE 176 BREAST CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 177 NORTH AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 178 EUROPE: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 179 ASIA PACIFIC: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 180 LATIN AMERICA: BREAST CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 181 MIDDLE EAST & AFRICA: BREAST CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)
           7.2.2 LUNG CANCER
                    7.2.2.1 Increasing focus on research for advanced treatment to drive segment
                                TABLE 182 LUNG CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 183 NORTH AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 184 EUROPE: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 185 ASIA PACIFIC: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 186 LATIN AMERICA: LUNG CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 187 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)
           7.2.3 PROSTATE CANCER
                    7.2.3.1 Rising number of research initiatives to propel market
                                TABLE 188 PROSTATE CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 189 NORTH AMERICA: PROSTATE CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 190 EUROPE: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 191 ASIA PACIFIC: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 192 LATIN AMERICA: PROSTATE CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 193 MIDDLE EAST & AFRICA: PROSTRATE CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)
           7.2.4 COLORECTAL CANCER
                    7.2.4.1 Increasing drug research activities to support market
                                TABLE 194 COLORECTAL CANCER MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 195 NORTH AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 196 EUROPE: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 197 ASIA PACIFIC: COLORECTAL CANCER MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 198 LATIN AMERICA: COLORECTAL CANCER MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 199 MIDDLE EAST & AFRICA: COLORECTAL CANCER MARKET, BY REGION,  2022–2029 (USD MILLION)
           7.2.5 OTHER CANCERS
                    TABLE 200 NUMBER OF DRUGS IN R&D PIPELINE FOR OTHER CANCERS, 2022 AND 2023
                    TABLE 201 OTHER CANCERS MARKET, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 202 NORTH AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 203 EUROPE: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 204 ASIA PACIFIC: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 205 LATIN AMERICA: OTHER CANCERS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 206 MIDDLE EAST & AFRICA: OTHER CANCERS MARKET, BY REGION,  2022–2029 (USD MILLION)
    7.3 INFECTIOUS DISEASES 
           7.3.1 GROWING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT MARKET
                    TABLE 207 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 208 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 209 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 210 ASIA PACIFIC: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 211 LATIN AMERICA: MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 212 MIDDLE EAST & AFRICA: MARKET FOR INFECTIOUS DISEASES,  BY REGION, 2022–2029 (USD MILLION)
    7.4 CARDIOVASCULAR SYSTEM DISORDERS 
           7.4.1 INCREASING PREVALENCE OF CARDIOVASCULAR DISEASES TO DRIVE MARKET
                    TABLE 213 EXAMPLES OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES  (AS OF DECEMBER 2023)
                    TABLE 214 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 215 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 216 EUROPE: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 217 ASIA PACIFIC: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 218 LATIN AMERICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 219 MIDDLE EAST & AFRICA: MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2022–2029 (USD MILLION)
    7.5 NEUROLOGY 
           7.5.1 INCREASING INVESTMENTS IN R&D TO DRIVE MARKET
                    TABLE 220 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 221 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 222 EUROPE: MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 223 ASIA PACIFIC: MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 224 LATIN AMERICA: MARKET FOR NEUROLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 225 MIDDLE EAST & AFRICA: MARKET FOR NEUROLOGY, BY REGION,  2022–2029 (USD MILLION)
    7.6 METABOLIC DISORDERS/ENDOCRINOLOGY 
           7.6.1 INCREASING NUMBER OF DIABETES PATIENTS TO BOOST MARKET
                    FIGURE 33 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES,  2000–2045 (MILLION)
                    TABLE 226 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 227 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 228 EUROPE: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 229 ASIA PACIFIC: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 230 LATIN AMERICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 231 MIDDLE EAST & AFRICA: MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2022–2029 (USD MILLION)
    7.7 IMMUNOLOGICAL DISORDERS 
           7.7.1 GROWING CLINICAL RESEARCH AND RISING NUMBER OF DRUGS IN R&D PIPELINE TO DRIVE MARKET
                    TABLE 232 EXAMPLES OF PIPELINE DRUGS FOR IMMUNOLOGICAL DISORDERS, 2023
                    TABLE 233 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 234 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 235 EUROPE: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 236 ASIA PACIFIC: MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 237 LATIN AMERICA: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 238 MIDDLE EAST & AFRICA: MARKET FOR IMMUNOLOGICAL DISORDERS,  BY REGION, 2022–2029 (USD MILLION)
    7.8 VACCINES 
           7.8.1 GROWING PREVALENCE OF INFECTIOUS DISEASES AND RISING GOVERNMENT FUNDING TO SUPPORT MARKET
                    TABLE 239 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 240 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 241 EUROPE: CRO SERVICES MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 242 ASIA PACIFIC: MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 243 LATIN AMERICA: MARKET FOR VACCINES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 244 MIDDLE EAST & AFRICA: MARKET FOR VACCINES, BY REGION,  2022–2029 (USD MILLION)
    7.9 PSYCHIATRY 
           7.9.1 GROWING CASES OF PSYCHIATRIC DISORDERS AND INCREASING INVESTMENT IN R&D TO DRIVE MARKET
                    TABLE 245 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 246 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 247 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 248 ASIA PACIFIC: MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 249 LATIN AMERICA: MARKET FOR PSYCHIATRY, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 250 MIDDLE EAST & AFRICA: MARKET FOR PSYCHIATRY, BY REGION,  2022–2029 (USD MILLION)
    7.10 RESPIRATORY DISORDERS 
           7.10.1 RISING INCIDENCE OF UNDIAGNOSED RESPIRATORY DISORDERS AMONG CHILDREN TO PROPEL MARKET
                     TABLE 251 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES, 2023
                     TABLE 252 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION,  2022–2029 (USD MILLION)
                     TABLE 253 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 254 EUROPE: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 255 ASIA PACIFIC: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 256 LATIN AMERICA: MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 257 MIDDLE EAST & AFRICA: MARKET FOR RESPIRATORY DISORDERS,  BY REGION, 2022–2029 (USD MILLION)
    7.11 DERMATOLOGY 
           7.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO SUPPORT MARKET
                     TABLE 258 LIST OF PIPELINE DRUGS FOR SKIN DISEASES, 2023
                     TABLE 259 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
                     TABLE 260 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 261 EUROPE: MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 262 ASIA PACIFIC: MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 263 LATIN AMERICA: MARKET FOR DERMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 264 MIDDLE EAST & AFRICA: MARKET FOR DERMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
    7.12 OPHTHALMOLOGY 
           7.12.1 RISING NUMBER OF PIPELINE DRUGS AND GROWING FOCUS ON R&D TO DRIVE MARKET
                     TABLE 265 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
                     TABLE 266 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 267 EUROPE: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 268 ASIA PACIFIC: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 269 LATIN AMERICA: MARKET FOR OPHTHALMOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 270 MIDDLE EAST & AFRICA: MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION)
    7.13 GASTROINTESTINAL DISEASES 
           7.13.1 INCREASING LEVELS OF OBESITY WITH LIFESTYLE AND DIETARY CHANGES TO DRIVE MARKET
                     TABLE 271 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION,  2022–2029 (USD MILLION)
                     TABLE 272 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 273 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 274 ASIA PACIFIC: MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 275 LATIN AMERICA: MARKET FOR GASTROINTESTINAL DISEASES,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 276 MIDDLE EAST & AFRICA: MARKET FOR GASTROINTESTINAL DISEASES,  BY REGION, 2022–2029 (USD MILLION)
    7.14 GENITOURINARY & WOMEN’S HEALTH 
           7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS AND INCREASING NUMBER OF PIPELINE DRUGS TO PROPEL MARKET
                     TABLE 277 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION,  2022–2029 (USD MILLION)
                     TABLE 278 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 279 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 280 ASIA PACIFIC: MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 281 LATIN AMERICA: MARKET FOR GENITOURINARY & WOMEN’S HEALTH,  BY COUNTRY, 2022–2029 (USD MILLION)
                     TABLE 282 MIDDLE EAST & AFRICA: MARKET FOR GENITOURINARY & WOMEN’S HEALTH, BY REGION, 2022–2029 (USD MILLION)
    7.15 HEMATOLOGY 
           7.15.1 GROWING PREVALENCE OF BLOOD-RELATED DISEASES TO SUPPORT MARKET
                     TABLE 283 CRO SERVICES MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION)
                     TABLE 284 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 285 EUROPE: MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 286 ASIA PACIFIC: MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 287 LATIN AMERICA: MARKET FOR HEMATOLOGY, BY COUNTRY,  2022–2029 (USD MILLION)
                     TABLE 288 MIDDLE EAST & AFRICA: MARKET FOR HEMATOLOGY, BY REGION,  2022–2029 (USD MILLION)
    7.16 OTHER THERAPEUTIC AREAS 
           TABLE 289 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION,  2022–2029 (USD MILLION)
           TABLE 290 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR OTHER THERAPEUTIC AREAS,  BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 291 EUROPE: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY,  2022–2029 (USD MILLION)
           TABLE 292 ASIA PACIFIC: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 293 LATIN AMERICA: MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2022–2029 (USD MILLION)
           TABLE 294 MIDDLE EAST & AFRICA: MARKET FOR OTHER THERAPEUTIC AREAS,  BY REGION, 2022–2029 (USD MILLION)
    7.17 CUSTOMIZATION 
           7.17.1 CELL & GENE THERAPY
                    7.17.1.1 Growing investments for advanced research initiatives to support market
                                TABLE 295 CRO SERVICES MARKET FOR CELL & GENE THERAPY, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 296 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 297 EUROPE: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 298 ASIA PACIFIC: MARKET FOR CELL & GENE THERAPY, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 299 LATIN AMERICA: MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 300 MIDDLE EAST & AFRICA: MARKET FOR CELL & GENE THERAPY,  BY REGION, 2022–2029 (USD MILLION)
           7.17.2 RARE DISEASES
                    7.17.2.1 Rising number of R&D activities for rare disease treatment to drive market
                                TABLE 301 CRO SERVICES MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 302 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 303 EUROPE: MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 304 ASIA PACIFIC: MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 305 LATIN AMERICA: MARKET FOR RARE DISEASES, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 306 MIDDLE EAST & AFRICA: MARKET FOR RARE DISEASES, BY REGION, 2022–2029 (USD MILLION)
           7.17.3 BIOSIMILARS
                    7.17.3.1 Growing focus on biosimilars and patent expiration of biologics to drive market
                                TABLE 307 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 308 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 309 EUROPE: CRO SERVICES MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 310 ASIA PACIFIC: MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 311 LATIN AMERICA: MARKET FOR BIOSIMILARS, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 312 MIDDLE EAST & AFRICA: MARKET FOR BIOSIMILARS, BY REGION,  2022–2029 (USD MILLION)
                                TABLE 313 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET FOR BIOSIMILARS, BY TYPE, 2022–2029 (USD MILLION)
                    7.17.3.2 Monoclonal antibodies
                                TABLE 314 MONOCLONAL ANTIBODIES MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 315 NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 316 EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 317 ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 318 LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 319 MIDDLE EAST & AFRICA: MONOCLONAL ANTIBODIES MARKET, BY REGION,  2022–2029 (USD MILLION)
                    7.17.3.3 Insulin
                                TABLE 320 INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 321 NORTH AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 322 EUROPE: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 323 ASIA PACIFIC: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 324 LATIN AMERICA: INSULIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 325 MIDDLE EAST & AFRICA: INSULIN MARKET, BY REGION, 2022–2029 (USD MILLION)
                    7.17.3.4 CSF
                                TABLE 326 CSF MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 327 NORTH AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 328 EUROPE: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 329 ASIA PACIFIC: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 330 LATIN AMERICA: CSF MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 331 MIDDLE EAST & AFRICA: CSF MARKET, BY REGION, 2022–2029 (USD MILLION)
                    7.17.3.5 Erythropoietin
                                TABLE 332 ERYTHROPOIETIN MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 333 NORTH AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 334 EUROPE: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 335 ASIA PACIFIC: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 336 LATIN AMERICA: ERYTHROPOIETIN MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 337 MIDDLE EAST & AFRICA: ERYTHROPOIETIN MARKET, BY REGION,  2022–2029 (USD MILLION)
                    7.17.3.6 Other biosimilars
                                TABLE 338 OTHER BIOSIMILARS MARKET, BY REGION, 2022–2029 (USD MILLION)
                                TABLE 339 NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY,  2022–2029 (USD MILLION)
                                TABLE 340 EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 341 ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 342 LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
                                TABLE 343 MIDDLE EAST & AFRICA: OTHER BIOSIMILARS MARKET, BY REGION,  2022–2029 (USD MILLION)
 
8 CRO SERVICES MARKET, BY END USER (Page No. - 276)
    8.1 INTRODUCTION 
          TABLE 344 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
    8.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 
           8.2.1 STABLE R&D PIPELINES AND INCREASED INVESTMENTS TO DRIVE MARKET
                    FIGURE 34 ANNUAL DRUG APPROVALS, BY CDER (FDA), 2012–2023
                    FIGURE 35 R&D SPENDING OF PHARMACEUTICAL MEMBER COMPANIES, 2012–2022
                    TABLE 345 CRO SERVICES MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
                    TABLE 346 NORTH AMERICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 347 EUROPE: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 348 ASIA PACIFIC: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 349 LATIN AMERICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 350 MIDDLE EAST & AFRICA: MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION, 2022–2029 (USD MILLION)
    8.3 MEDICAL DEVICE COMPANIES 
           8.3.1 INCREASING NUMBER OF GROWTH INITIATIVES BY MEDTECH ORGANIZATIONS TO DRIVE MARKET
                    FIGURE 36 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2012–2023)
                    TABLE 351 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 352 NORTH AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 353 EUROPE: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 354 ASIA PACIFIC: MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 355 LATIN AMERICA: MARKET FOR MEDICAL DEVICE COMPANIES,  BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 356 MIDDLE EAST & AFRICA: MARKET FOR MEDICAL DEVICE COMPANIES,  BY REGION, 2022–2029 (USD MILLION)
    8.4 ACADEMIC INSTITUTES 
           8.4.1 RISING NUMBER OF COLLABORATIONS BETWEEN CONTRACT RESEARCH ORGANIZATIONS AND ACADEMIA TO DRIVE MARKET
                    TABLE 357 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION,  2022–2029 (USD MILLION)
                    TABLE 358 NORTH AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 359 EUROPE: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 360 ASIA PACIFIC: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,  2022–2029 (USD MILLION)
                    TABLE 361 LATIN AMERICA: MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION)
                    TABLE 362 MIDDLE EAST & AFRICA: MARKET FOR ACADEMIC INSTITUTES,  BY REGION, 2022–2029 (USD MILLION)
 
9 CRO SERVICES MARKET, BY REGION (Page No. - 289)
    9.1 INTRODUCTION 
          TABLE 363 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION, 2022–2029 (USD MILLION)
    9.2 NORTH AMERICA 
          FIGURE 37 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET SNAPSHOT
          TABLE 364 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 365 NORTH AMERICA: MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 366 NORTH AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)
          TABLE 367 NORTH AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 368 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 369 NORTH AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 370 NORTH AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 371 NORTH AMERICA: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
          TABLE 372 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 373 NORTH AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.2.1 NORTH AMERICA: RECESSION IMPACT
           9.2.2 US
                    9.2.2.1 US to dominate North American CRO services market during forecast period
                                FIGURE 38 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION  (JANUARY 2022 VS. JANUARY 2023)
                                TABLE 374 US: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 375 US: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 376 US: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 377 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 378 US: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 379 US: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 380 US: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 381 US: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 382 US: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.2.3 CANADA
                    9.2.3.1 Short approval time and favorable government R&D investments to drive market
                                TABLE 383 CANADA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 384 CANADA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 385 CANADA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 386 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 387 CANADA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 388 CANADA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 389 CANADA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 390 CANADA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 391 CANADA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.3 EUROPE 
          TABLE 392 EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 393 EUROPE: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 394 EUROPE: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
          TABLE 395 EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 396 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 397 EUROPE: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 398 EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 399 EUROPE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
          TABLE 400 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 401 EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.1 EUROPE: RECESSION IMPACT
           9.3.2 GERMANY
                    9.3.2.1 Growing R&D spending and favorable government policies to propel market
                                TABLE 402 GERMANY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 403 GERMANY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                                TABLE 404 GERMANY: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 405 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 406 GERMANY: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 407 GERMANY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 408 GERMANY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 409 GERMANY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 410 GERMANY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.3 UK
                    9.3.3.1 Growth in R&D expenditure in pharmaceutical industry to boost market
                                TABLE 411 UK: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 412 UK: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 413 UK: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 414 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 415 UK: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 416 UK: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 417 UK: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 418 UK: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 419 UK: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.4 FRANCE
                    9.3.4.1 Government support for effective drug research to drive market growth
                                TABLE 420 FRANCE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 421 FRANCE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 422 FRANCE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 423 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 424 FRANCE: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 425 FRANCE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 426 FRANCE: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 427 FRANCE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 428 FRANCE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.5 ITALY
                    9.3.5.1 Increased availability of funding for drug discovery and development to drive market
                                TABLE 429 ITALY: NUMBER OF CLINICAL TRIALS IN ITALY, BY COMPANY (JANUARY 2022 VS. JANUARY 2023)
                                TABLE 430 ITALY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 431 ITALY: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 432 ITALY: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 433 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 434 ITALY: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 435 ITALY: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 436 ITALY: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 437 ITALY: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 438 ITALY: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.6 SPAIN
                    9.3.6.1 Growing R&D expenditure to boost market
                                TABLE 439 SPAIN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 440 SPAIN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 441 SPAIN: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 442 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 443 SPAIN: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 444 SPAIN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 445 SPAIN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 446 SPAIN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 447 SPAIN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.3.7 REST OF EUROPE
                    TABLE 448 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 449 REST OF EUROPE: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)
                    TABLE 450 REST OF EUROPE: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 451 REST OF EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 452 REST OF EUROPE: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 453 REST OF EUROPE: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 454 REST OF EUROPE: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                    TABLE 455 REST OF EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 456 REST OF EUROPE: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.4 ASIA PACIFIC 
          FIGURE 39 ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET SNAPSHOT
          TABLE 457 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 458 ASIA PACIFIC: MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 459 ASIA PACIFIC: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
          TABLE 460 ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
          TABLE 461 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 462 ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 463 ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 464 ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
          TABLE 465 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 466 ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.1 ASIA PACIFIC: RECESSION IMPACT
           9.4.2 CHINA
                    9.4.2.1 Low manufacturing cost and increased establishment of R&D centers to drive market
                                TABLE 467 CHINA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 468 CHINA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 469 CHINA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 470 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 471 CHINA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 472 CHINA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 473 CHINA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 474 CHINA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 475 CHINA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Growth in pharmaceutical industry and favorable scenario for foreign direct investment to propel market
                                TABLE 476 INDIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 477 INDIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 478 INDIA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 479 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 480 INDIA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 481 INDIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 482 INDIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 483 INDIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 484 INDIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.4 JAPAN
                    9.4.4.1 Decline in number of clinical trials to limit market
                                TABLE 485 JAPAN: TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA,  2020, 2022, AND 2023
                                TABLE 486 JAPAN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 487 JAPAN: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 488 JAPAN: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 489 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 490 JAPAN: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 491 JAPAN: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 492 JAPAN: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 493 JAPAN: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 494 JAPAN: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.5 AUSTRALIA
                    9.4.5.1 Favorable tax incentives and cash rebates to pharmaceutical companies to support market
                                TABLE 495 AUSTRALIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 496 AUSTRALIA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                                TABLE 497 AUSTRALIA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 498 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 499 AUSTRALIA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 500 AUSTRALIA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 501 AUSTRALIA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 502 AUSTRALIA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 503 AUSTRALIA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.6 SOUTH KOREA
                    9.4.6.1 Favorable government initiatives for drug development to drive market
                                TABLE 504 SOUTH KOREA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 505 SOUTH KOREA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                                TABLE 506 SOUTH KOREA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 507 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 508 SOUTH KOREA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 509 SOUTH KOREA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 510 SOUTH KOREA: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                                TABLE 511 SOUTH KOREA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 512 SOUTH KOREA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.7 NEW ZEALAND
                    9.4.7.1 Rising number of key players and growing R&D activities to support market
                                TABLE 513 NEW ZEALAND: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 514 NEW ZEALAND: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                                TABLE 515 NEW ZEALAND: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 516 NEW ZEALAND: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 517 NEW ZEALAND: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 518 NEW ZEALAND: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 519 NEW ZEALAND: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                                TABLE 520 NEW ZEALAND: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 521 NEW ZEALAND: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.4.8 REST OF ASIA PACIFIC
                    TABLE 522 REST OF ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 523 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)
                    TABLE 524 REST OF ASIA PACIFIC: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 525 REST OF ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 526 REST OF ASIA PACIFIC: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 527 REST OF ASIA PACIFIC: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 528 REST OF ASIA PACIFIC: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                    TABLE 529 REST OF ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 530 REST OF ASIA PACIFIC: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER,  2022–2029 (USD MILLION)
    9.5 LATIN AMERICA 
          TABLE 531 LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
          TABLE 532 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 533 LATIN AMERICA: MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
          TABLE 534 LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 535 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 536 LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 537 LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 538 LATIN AMERICA: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
          TABLE 539 LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 540 LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.5.1 LATIN AMERICA: RECESSION IMPACT
           9.5.2 BRAZIL
                    9.5.2.1 Increased government investments in pharmaceutical R&D to drive market
                                TABLE 541 BRAZIL: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 542 BRAZIL: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 543 BRAZIL: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 544 BRAZIL: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 545 BRAZIL: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 546 BRAZIL: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 547 BRAZIL: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 548 BRAZIL: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 549 BRAZIL: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.5.3 MEXICO
                    9.5.3.1 Favorable government policies for R&D and manufacturing to drive market
                                TABLE 550 MEXICO: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 551 MEXICO: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 552 MEXICO: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 553 MEXICO: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 554 MEXICO: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 555 MEXICO: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 556 MEXICO: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 557 MEXICO: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 558 MEXICO: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.5.4 REST OF LATIN AMERICA
                    TABLE 559 REST OF LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 560 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                    TABLE 561 REST OF LATIN AMERICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 562 REST OF LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 563 REST OF LATIN AMERICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                    TABLE 564 REST OF LATIN AMERICA: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 565 REST OF LATIN AMERICA: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                    TABLE 566 REST OF LATIN AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                    TABLE 567 REST OF LATIN AMERICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA 
          TABLE 568 MIDDLE EAST & AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY REGION,  2022–2029 (USD MILLION)
          TABLE 569 MIDDLE EAST & AFRICA: CRO SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 570 MIDDLE EAST & AFRICA: MARKET FOR CLINICAL RESEARCH SERVICES,  BY PHASE, 2022–2029 (USD MILLION)
          TABLE 571 MIDDLE EAST & AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 572 MIDDLE EAST & AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 573 MIDDLE EAST & AFRICA: MARKET FOR LABORATORY SERVICES, BY TYPE, 2022–2029 (USD MILLION)
          TABLE 574 MIDDLE EAST & AFRICA: ANALYTICAL TESTING MARKET, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 575 MIDDLE EAST & AFRICA: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
          TABLE 576 MIDDLE EAST & AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
          TABLE 577 MIDDLE EAST & AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER,  2022–2029 (USD MILLION)
           9.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
           9.6.2 MIDDLE EAST
                    9.6.2.1 Increase in clinical research activities to drive market
                                TABLE 578 MIDDLE EAST: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 579 MIDDLE EAST: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE, 2022–2029 (USD MILLION)
                                TABLE 580 MIDDLE EAST: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES,  BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 581 MIDDLE EAST: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 582 MIDDLE EAST: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 583 MIDDLE EAST: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 584 MIDDLE EAST: MARKET, BY THERAPEUTIC AREA,  2022–2029 (USD MILLION)
                                TABLE 585 MIDDLE EAST: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 586 MIDDLE EAST: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
           9.6.3 AFRICA
                    9.6.3.1 Growth in pharmaceutical industry to support market
                                TABLE 587 AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 588 AFRICA: CRO SERVICES MARKET FOR CLINICAL RESEARCH SERVICES, BY PHASE,  2022–2029 (USD MILLION)
                                TABLE 589 AFRICA: MARKET FOR EARLY-PHASE DEVELOPMENT SERVICES, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 590 AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 591 AFRICA: MARKET FOR LABORATORY SERVICES, BY TYPE,  2022–2029 (USD MILLION)
                                TABLE 592 AFRICA: ANALYTICAL TESTING MARKET, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 593 AFRICA: MARKET, BY THERAPEUTIC AREA, 2022–2029 (USD MILLION)
                                TABLE 594 AFRICA: CRO SERVICES MARKET FOR ONCOLOGY, BY TYPE, 2022–2029 (USD MILLION)
                                TABLE 595 AFRICA: CONTRACT RESEARCH ORGANIZATION SERVICES MARKET, BY END USER, 2022–2029 (USD MILLION)
 
10 COMPETITIVE LANDSCAPE (Page No. - 403)
     10.1 INTRODUCTION 
     10.2 KEY STRATEGIES/RIGHT TO WIN 
             FIGURE 40 STRATEGIES ADOPTED BY KEY PLAYERS IN CONTRACT RESEARCH ORGANIZATION SERVICES MARKET
     10.3 REVENUE SHARE ANALYSIS 
             FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS, 2021–2023 (USD BILLION)
     10.4 MARKET SHARE ANALYSIS 
             FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2023
             TABLE 596 DEGREE OF COMPETITION: CRO SERVICES MARKET
     10.5 COMPANY EVALUATION MATRIX 
             10.5.1 STARS
             10.5.2 EMERGING LEADERS
             10.5.3 PERVASIVE PLAYERS
             10.5.4 PARTICIPANTS
                        FIGURE 43 COMPANY EVALUATION MATRIX, 2023
             10.5.5 COMPANY FOOTPRINT
                        TABLE 597 INDUSTRY FOOTPRINT
                        TABLE 598 SERVICE FOOTPRINT
                        TABLE 599 REGIONAL FOOTPRINT
     10.6 START-UP/SME EVALUATION MATRIX 
             10.6.1 PROGRESSIVE COMPANIES
             10.6.2 RESPONSIVE COMPANIES
             10.6.3 DYNAMIC COMPANIES
             10.6.4 STARTING BLOCKS
                        FIGURE 44 START-UP/SME EVALUATION MATRIX, 2023
             10.6.5 COMPETITIVE BENCHMARKING
                        TABLE 600 DETAILED LIST OF KEY START-UPS/SMES
                        TABLE 601 COMPETITIVE BENCHMARKING OF START-UPS/SMES
     10.7 COMPETITIVE SCENARIOS & TRENDS 
             10.7.1 KEY SERVICES LAUNCHES
                        TABLE 602 KEY SERVICE LAUNCHES, JANUARY 2020–SEPTEMBER 2023
             10.7.2 KEY DEALS
                        TABLE 603 KEY DEALS, JANUARY 2020– SEPTEMBER 2023
             10.7.3 OTHER KEY DEVELOPMENTS
                        TABLE 604 KEY EXPANSIONS, JANUARY 2020– SEPTEMBER 2023
 
11 COMPANY PROFILES (Page No. - 417)
     11.1 KEY PLAYERS 
(Business overview, Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats)*
             11.1.1 IQVIA INC.
                        TABLE 605 IQVIA INC.: COMPANY OVERVIEW
                        FIGURE 45 IQVIA INC.: COMPANY SNAPSHOT (2022)
             11.1.2 ICON PLC
                        TABLE 606 ICON PLC: COMPANY OVERVIEW
                        FIGURE 46 ICON PLC: COMPANY SNAPSHOT (2022)
             11.1.3 THERMO FISHER SCIENTIFIC INC.
                        TABLE 607 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
                        FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022)
             11.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
                        TABLE 608 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
                        FIGURE 48 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022)
             11.1.5 SYNEOS HEALTH
                        TABLE 609 SYNEOS HEALTH: COMPANY OVERVIEW
                        FIGURE 49 SYNEOS HEALTH: COMPANY SNAPSHOT (2022)
             11.1.6 WUXI APPTEC
                        TABLE 610 WUXI APPTEC: COMPANY OVERVIEW
                        FIGURE 50 WUXI APPTEC: COMPANY SNAPSHOT (2022)
             11.1.7 CHARLES RIVER LABORATORIES
                        TABLE 611 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
                        FIGURE 51 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022)
             11.1.8 PAREXEL INTERNATIONAL CORPORATION
                        TABLE 612 PAREXEL INTERNATIONAL CORPORATION: COMPANY OVERVIEW
             11.1.9 PHARMARON
                        TABLE 613 PHARMARON: COMPANY OVERVIEW
                        FIGURE 52 PHARMARON: COMPANY SNAPSHOT (2022)
             11.1.10 FORTREA, INC.
                        TABLE 614 FORTREA, INC.: COMPANY OVERVIEW
                        FIGURE 53 FORTREA, INC.: COMPANY SNAPSHOT (2022)
             11.1.11 MEDPACE
                        TABLE 615 MEDPACE: COMPANY OVERVIEW
                        FIGURE 54 MEDPACE: COMPANY SNAPSHOT (2022)
             11.1.12 SGS SA
                        TABLE 616 SGS SA: COMPANY OVERVIEW
                        FIGURE 55 SGS SA: COMPANY SNAPSHOT (2022)
             11.1.13 FRONTAGE LABS
                        TABLE 617 FRONTAGE LABS: COMPANY OVERVIEW
                        FIGURE 56 FRONTAGE LABS: COMPANY SNAPSHOT (2022)
             11.1.14 EUROFINS SCIENTIFIC
                        TABLE 618 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
                        FIGURE 57 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022)
             11.1.15 PSI CRO AG
                        TABLE 619 PSI CRO AG: COMPANY OVERVIEW
             11.1.16 BIOAGILE
                        TABLE 620 BIOAGILE: COMPANY OVERVIEW
             11.1.17 FIRMA CLINICAL RESEARCH
                        TABLE 621 FIRMA CLINICAL RESEARCH: COMPANY OVERVIEW
             11.1.18 ACCULAB LIFE SCIENCES
                        TABLE 622 ACCULAB LIFE SCIENCES: COMPANY OVERVIEW
             11.1.19 NOVOTECH
                        TABLE 623 NOVOTECH: COMPANY OVERVIEW
             11.1.20 KCR S.A.
                        TABLE 624 KCR S.A.: COMPANY OVERVIEW
             11.1.21 LINICAL
                        TABLE 625 LINICAL: COMPANY OVERVIEW
             11.1.22 ADVANCED CLINICAL
                        TABLE 626 ADVANCED CLINICAL: COMPANY OVERVIEW
     11.2 OTHER PLAYERS 
             11.2.1 ALLUCENT
             11.2.2 CLINICAL TRIAL SERVICE
             11.2.3 GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.)
             11.2.4 WORLDWIDE CLINICAL TRIALS
             11.2.5 CTI CLINICAL TRIAL & CONSULTING
 
*Details on Business overview, Services/Solutions offered, Recent developments, MnM view, Key strengths/Right to win, Strategic choices made, and Weaknesses and Competitive threats might not be captured in case of unlisted companies.
 
12 APPENDIX (Page No. - 500)
     12.1 DISCUSSION GUIDE 
     12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’  SUBSCRIPTION PORTAL 
     12.3 CUSTOMIZATION OPTIONS 
     12.4 RELATED REPORTS 
     12.5 AUTHOR DETAILS 

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global CRO Services market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from public sources, such as the Association of Clinical Research Organizations (ACRO), Clinical Research Society (CRS), Clinical Research Association of Canada (CRAC), Association of International Contract Research Organizations (AICRO), Clinical and Contract Research Association (CCRA), ClinicalTrials.gov website, American Association of Pharmaceutical Scientists (AAPS), Eurostat, Food and Drug Administration (FDA), Pharmaceutical Research and Manufacturers of America (PhRMA), Japan CRO Association, Chinese Association for Laboratory Animal Sciences (CALAS), and Indian Society for Clinical Research (ISCR) among others. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; business and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global CRO Services market, which was validated through primary research.

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global CRO services market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (personnel from pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes) and supply side (C-level and D-level executives, product managers, and marketing and sales managers of key manufacturers, distributors, and channel partners, among others, from Tier 1 and Tier 2 companies engaged in offering services) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 70% of primary interviews were conducted with supply-side representatives, while demand-side participants accounted for the remaining share. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Contract  Research Organization (CRO) Services market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the CRO services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Global CRO Services Market Size: Bottom Up Approach

Bottom-up approach was used to estimate and validate the total size of the CRO Services market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:  

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the CRO Services business of leading players have been determined through primary and secondary research
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Contract Research Organization (CRO) Services market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global CRO Services Market Size: Top Down Approach

Contract Research Organization (CRO) Services market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from the supply side majorly.

Market Definition

CROs are companies that offer research services on a contract basis to various pharmaceutical and biotechnology companies, medical device companies, and academic institutes. These services include clinical research services, early-phase development services, laboratory services, consulting services, and data management services. A sponsor (i.e., a company investigating the safety and efficacy of new drugs, therapies, or medical devices) partners with a CRO on a contractual or project-by-project basis. The CRO provides advice and guidance for planning, designing, and executing clinical trials; it offers a comprehensive and diverse range of services for each phase of the clinical trial.

Key Stakeholders

  • Pharmaceutical & biopharmaceutical companies
  • Medical device manufacturing companies
  • Academic & research institutes
  • Venture capitalists & investors
  • Market research & consulting firms
  • Government associations
  • Medical institutions & universities

Report Objectives

  • To define, describe, and forecast the contract research organization (CRO) services market based on type, therapeutic area, end user, and region
  • To provide detailed information regarding the major factors influencing the market growth (drivers, opportunities, and challenges) along with the current trends
  • To strategically analyze micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of market segments with respect to five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
  • To profile the key players and comprehensively analyze their market shares and core competencies
  • To track and analyze competitive developments in the CRO services market, such as service launches, agreements, partnerships, collaborations, mergers & acquisitions, and research & development activities

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Service Matrix, which gives a detailed comparison of the service portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to 5).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific CRO services market into countries
  • A further breakdown of the Rest of European CRO services market into countries
  • A further breakdown of the Rest of Latin American CRO services market into countries
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
PH 4672
Published ON
Jan, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Contract Research Organization Services Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback